Onychomysosis - I-Onychomysosis
☆ Emiphumeleni ka-2022 ye-Stiftung Warentest evela eJalimane, ukwaneliseka kwabathengi nge-ModelDerm bekungaphansi kancane kunokuxhumana okukhokhelwayo kwe-telemedicine.
Uzipho lozwane luthinteke I-Onychomysosis (Onychomysosis)
Unyawo lomuntu olunesifo sokukhunta izinzipho amasonto ayishumi enkambweni yomuthi womlomo we-terbinafine. Qaphela ibhande lokukhula kwezinzipho ezinempilo ngemuva kwezinzipho ezisele ezinegciwane.
References
Ama-antifungal e-systemic ayindlela yokwelapha ephumelela kakhulu. Ukuhlaziywa kwe-Meta kubonisa amazinga okwelapha e-mycotic kanje: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48% . Ukuchithwa kwe-nail okuhambisanayo kwandisa amazinga okwelapha. Ukwelapha ngezihloko nge- ciclopirox akusebenzi kahle; inezinga lokwehluleka elingaphezu kuka-60%.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
I-Onychomycosis yisifo sokukhunta esithinta izinzipho. Uma ibangelwa ama-dermatophyte, ibizwa ngokuthi i-tinea unguium. I-Onychomycosis ihlanganisa izifo ezibangelwa ama-dermatophytes, imvubelo, nesikhunta. Inkinga yezinzipho engabangelwa ukutheleleka kwefungal ibizwa ngokuthi nail dystrophy. Nakuba kungathinta kokubili izinzipho nezinzwane, i-toenail onychomycosis ivame kakhulu. Lesi sihloko sidingida izici ezihlukahlukene ze-toenail onychomycosis, njengomthelela wayo, izinhlobo zomtholampilo, izigaba, ukuxilongwa, nokwelashwa. Nakuba kungekona ukuphila engozini, i-onychomycosis ingaholela ezinkingeni ezinkulu njenge-cellulitis, i-sepsis, ukutheleleka kwamathambo, ukulimala kwezicubu, nokulahlekelwa kwezinzipho.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
Terbinafine umuthi olwa nezifo ezikhunta ngokuvimba i-squalene epoxidase. Isebenza ngempumelelo ngokumelene nezinhlobo eziningi zesikhunta sesikhumba futhi ivunyelwe ukwelapha ukhunta wezinzipho lapho ithathwa ngomlomo. Nakuba imiphumela engemihle eminingi efana nekhanda elibuhlungu nezinkinga zesisu mincane futhi iyazihambela, izinguquko ekunambithekeni kwazo (dysgeusia) zingahluka ukusuka kokuncane kuye kokunzima, ngezinye izikhathi okuholela ekwehleni kwesisindo. Izinguquko ezihlala njalo zokunambitheka azivamile kodwa zibikiwe.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
I-Onychomycosis ukutheleleka kwefungal okuthinta izinzipho. Cishe u-90% wezifo zozipho lukazwane kanye nama-75% ezinzipho ezibangelwa yisikhunta (Trichophyton mentagrophytes, Trichophyton rubrum) . Izimpawu zihlanganisa ukushintsha kombala wezinzipho, ukuqina, ukuhlukana nombhede wezinzipho, nokukhula ngokweqile. Ukwelashwa ngokuvamile kuhilela imishanguzo yomlomo efana ne-terbinafine noma i-itraconazole, nokwelashwa kwetopic okuyindlela yokuzikhethela ezimeni ezithambile nezilingene.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.
Umuthi we-antifungal i-terbinafine othathwe ngomlomo ubonakala uphumelela kakhulu kodwa i-terbinafine ihlotshaniswa nomthelela oseceleni wesibindi.
i-onychomysosis (onychomysosis) kwenzeka cishe kumaphesenti angu-10 wabantu abadala, nabantu abadala abavame ukuthinteka kakhulu. Abesilisa bathinteka kakhulu kunabesifazane. i-onychomysosis (onychomysosis) imele cishe uhhafu wesifo sezinzipho. Lokhu kusho ukuthi ukukhubazeka kwezinzwane nakho kungavela kwezinye izimbangela ngaphandle kwe-onychomycosis.
○ Ukwelashwa - Izidakamizwa ze-OTC
Kunzima ukwelapha i-onychomycosis ngemithi ye-topical ngoba kunzima ukuthi izidakamizwa zingene ezinzwaneni eziqinisiwe.
#Ketoconazole
#Clotrimazole
#Miconazole
#Terbinafine
#Butenafine [Lotrimin]
#Tolnaftate
○ Ukwelashwa
Ukwelashwa isikhathi eside kuvame ukudingeka kuze kube yilapho uzipho olunegciwane lukhishwa ngokuphelele.
#Terbinafine (oral)
#Itraconazole
#Efinaconazole lacquer [Jublia]
#Ciclopirox lacquer